ClinicalTrials.gg
RecruitingNCT07476469Updated Apr 23, 2026

tVNS and Approach-Avoidance Behavior in Anhedonia and Anxiety

An interventional study of tVNS and Sham in Healthy Participants, Anxiety Disorders (With High Anxiety Symptoms) and Depressive Disorders (With High Anhedonia Symptoms), sponsored by Dr. Nils B. Kroemer. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Dr. Nils B. Kroemer · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Anxiety Disorders with a site in Germany — 27 open to participants now, 30 under way, none of them phase 3. Anxiety Disorders · Germany.

Planned enrollment
57th of 99
104 · median 138
Started
2026
with 5 others
No phase
76 of 133
21 open now
Primary completion
2027-12
later than 26 of 29 live
Registered
130th of 133
by date

Among the 133 studies in Anxiety Disorders with a site in Germany, this one is the 57th largest by planned enrollment of the 99 interventional ones that give a count, is one of 6 that started in 2026, is one of 76 with no phase, reaches primary completion later than 26 of the 29 other live ones, and was the 130th registered.

Anxiety Disorders

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

Browse Anxiety Disorders studies →

Open to participants now

27 of the 133 studies in Anxiety Disorders with a site in Germany are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Anxiety Disorders with a site in Germany, or all of them as a file.
02

Study summary

This study investigates if anhedonia and anxiety symptoms are associated with alterations in reinforcement learning, effort trade-offs for wins vs. punishments, and foraging behavior under threat. Moreover, it will investigate whether these processes can be influenced by a metabolic load and/or transcutaneous vagus nerve stimulation (tVNS). The project consists of (a) an online reinforcement learning study, used to characterize learning, reward sensitivity, and meta-cognition, and (b) a laboratory study in which participants first undergo fMRI while completing an effort-based decision-making task. Second, participants will complete two sessions in VR with randomized active or sham tVNS during a foraging task before and after a caloric load with concurrent physiological recordings.

Read the detailed description

The overarching goal of this project is to investigate the potential of modulating internal signals in patients with mood and anxiety disorders to improve the balance between approach and avoidance behavior. To this end, tVNS (vs. sham) will be used to alter foraging behavior under threat.

To address the inherent heterogeneity of symptoms, it is planned to recruit participants with anxiety symptoms (ANX), anhedonia symptoms (ANH), both anxiety and mood symptoms (ANX+ANH), and healthy control participants (HCP). The groups will be matched for the group-average and distribution of age, sex, and BMI (age: 18 to 40 years, BMI 18.5 - 30 kg/m²). After an online assessment, diagnostic visit, and MRl-based phenotyping, internal signals are targeted with tVNS and a caloric load to shift the approach-avoidance behavior. In a randomized crossover study, participants will receive stimulation (tVNS or sham) in a hungry state (>4 h after the last meal at a time when they would typically have their next meal) and complete a VR-based foraging task under threat. They will then receive a standardized caloric load (milkshake containing \~400 kcal) and repeat the task with the same stimulation in a different metabolic state (postprandial). Crucially, participants can move freely during the task so that behavioral adaptations in response to threats (e.g., escaping a panther) as well as physiological adaptations (e.g., heart rate) and their recovery can be measured.

The study is split into three parts:

  1. Online screening and behavioral characterization At least 250 participants (≥150 with clinically relevant symptoms; STICSA >= 43 and/or SHAPS > 29.5) will complete baseline questionnaires (anhedonia (SHAPS, TEPS, and DARS), anxiety (STICSA and STAI), depression (BDI), substance abuse) and an approx. two weeks online reinforcement learning task (10 runs). Behavioral indices (choices, response times) and computational modeling parameters (e.g., learning rates, reward sensitivity, decision noise) will be derived. At the end of each run, participants provide metacognitive performance ratings, enabling assessment of deviations between subjective and objective performance.
  2. Neural correlates of approach-avoidance (phenotyping) A subset of participants (high anxiety, high anhedonia, combined, and healthy controls (STICSA \<= 40 and SHAPS \< 23.5); \~26 per group) will undergo laboratory-based testing. Assessments include diagnostic interviews, fasting blood samples (glucose, insulin, triglycerides, cortisol), and fMRI during an effort trade-off task comparing the effort to gain rewards and to avoid punishments.
  3. tVNS intervention The same participants will then complete a randomized, sham-controlled crossover trial. Participants will perform a VR foraging task under threat in two metabolic states: hungry (>4 h fasted) and postprandial (following a standardized caloric load \~400kcal). During both states, participants will receive either active or sham tVNS. Behavioral outcomes will be combined with physiological measures (e.g., heart rate) to assess the effects of vagal stimulation on approach-avoidance trade-offs.

Hypotheses:

  1. Patients with more severe anxiety symptoms are more sensitive to punishments. Thus, they spend less time foraging under threat and gain fewer rewards. In contrast, patients with more severe anhedonia symptoms are less sensitive to rewards. Thus, their overall foraging rate will be lower, leading to fewer rewards independent of threat.
  2. Behavioral and self-rated differences in learning from rewards and punishments are reflected in altered brain responses when making effort-based choices to either approach rewards or avoid punishments.
  3. A hungry state will reduce anxiety-like behavior and increase the approach of rewards.
  4. tVNS will enhance the anxiolytic effects of hunger by increasing the weight on internal signals of metabolic demand, facilitating the approach of rewards. In contrast, it will facilitate avoidance in a postprandial state.
  5. Inter-individual differences in the balance between motivational and threat-related circuits during the effort trade off task will predict tVNS effects when foraging.

Enrollment:

In the online assessment, at least 250 participants will be included to investigate differences in learning from wins and losses and how well behavioral shifts align with self-evaluation of performance. The sample size allows detecting even small effects that are likely in psychiatric research (r = .20) with a high power (1-β = 0.89). If necessary, further participants will be recruited for the online sample until the planned sample of N=104 participants has completed the tVNS intervention. For the phenotyping and the subsequent intervention study, 104 participants from 4 groups combining low/high anxiety and low/high anhedonia will be reinvited. With this transdiagnostic approach, the effects of anhedonia and anxiety on approach-avoid behavior can be disentangled. Crucially, oversampling participants with either high or low symptoms will maximize the expected effect size. The sample allows for evaluation of medium correlations (r = .30) between symptoms and approach-avoid trade-offs with a power of 1-β = 0.89. For the tVNS intervention, a sample of 104 participants allows for the conclusive study of medium-sized effects (dz = .40) observed in previous work (Neuser et al., 2020) with very high power (1-β = 0.98) across the sample. Differences in the tVNS response between participants (medium effect size, r = .30) can be evaluated with a power of 1-β = 0.89.

03

Conditions studied

  • Healthy Participants
  • Anxiety Disorders (With High Anxiety Symptoms)
  • Depressive Disorders (With High Anhedonia Symptoms)
  • Comorbid Depression and Anxiety Disorder (With High Anhedonia and High Anxiety Symptoms)

Keywords

  • Depression
  • Anhedonia
  • Anxiety
  • Vagusnerv-Stimulation
  • tVNS
  • Virtual Reality
  • fMRI
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18,5 and 30,0 kg/m2,
  • between 18 and 40 years of age, and
  • be able and willing to provide .

Exclusion criteria

Exclusion Criteria:

  • have a high risk of suicide,
  • have a lifetime diagnosis of severe neurological disorder (incl. ADHD), schizophrenia, bipolar disorder, or severe substance abuse, posttraumatic stress disorder, obsessive-compulsive disorder, diabetes, epilepsy, or coronary heart disease
  • have fulfilled criteria for an eating disorder or somatic symptom disorder within the last 12-months,
  • take medication (except psychopharmacological medication for MDD or anxiety), patients have to be on stable psychopharmacological medication for at least two months before study participation (minimizing confounding effects)
  • for MRI (metal implants or claustrophobia)
  • for female individuals if they are pregnant or nursing at the time,
  • impaired movement ability or hearing
  • impaired, uncorrected vision (need contact lenses)
  • contraindications for tVNS hearing aids or diseased skin on the right ear.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Healthy Controls

    The healthy control group will include participants without clinically relevant symptoms of anxiety or anhedonia. Inclusion criteria are a STICSA total score \<= 40 and a SHAPS total score below 23.5. Participants in this group must not meet the criteria for a current psychiatric diagnosis defined in the exclusion criteria, as confirmed by the Structured Clinical Interview for DSM (SCID).

    Device: tVNS · Device: Sham

  • Experimental
    Anxiety

    The anxiety group will include participants with elevated anxiety symptoms, defined as a STICSA total score \>= 43. All participants must meet diagnostic criteria for a current anxiety disorder or/and current depressive disorder, confirmed by the SCID.

    Device: tVNS · Device: Sham

  • Experimental
    Anhedonia

    The anhedonia group will include participants with elevated anhedonia symptoms, defined as a SHAPS total score greater than 29.5. All participants must meet diagnostic criteria for a current depressive disorder or/and current anxiety disorder, confirmed by the SCID.

    Device: tVNS · Device: Sham

  • Experimental
    Comorbid anhedonia and anxiety

    The combined group will include participants with both elevated anxiety and anhedonia symptoms, defined as STICSA \>= 43 and SHAPS \> 29.5, respectively. All participants must meet diagnostic criteria for a current anxiety disorder or/and a current depressive disorder, confirmed by the SCID.

    Device: tVNS · Device: Sham

Interventions

  • DevicetVNS

    The intervention consists of event-triggered tVNS in the form of short pulses (\~1-5s; frequency: 25Hz). A non-CE-certified and non-medical device (tVNS® R tVNS technologies, for research purposes) will be used. Stimulation intensity will be individually calibrated to ensure perceptible (mild pricking) but non-painful stimulation for each participant. The protocol is the same for all groups.

  • DeviceSham

    The sham condition similarly consists of event-triggered, closed-loop stimulation, but without vagus nerve activation (short pulses of 1-5s; frequency: 25Hz). A non-CE-certified and non-medical device (tVNS® R, for research purposes) will be used. The manufacturer is not involved in the study. Stimulation intensity will be individually calibrated to ensure perceptible (mild pricking) but non-painful stimulation for each participant. The protocol is the same for all groups.

06

What researchers measure

Primary outcomes

  1. Stimulation-induced changes in the number of rewards collected under threat (VR foraging task)

    The number of rewards collected during a VR foraging task will be compared between stimulation conditions (tVNS vs. sham).

    Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)

  2. BOLD response during the effort-trade-off task (offer-phase)

    The outcome describes task-evoked neural activation (BOLD response) during the offer phase of the effort trade-off task. Neural activation is measured as a task-evoked BOLD response during offer presentation.

    Time frame: Collected during fMRI session (single session throughout study completion ~35min per participant)

  3. Reward learning

    Reward learning is repeatedly measured during an online bandit task with fluctuating reward probabilities. Reward learning behavior will be collected online in 10 runs spread over 5 to 10 days, each including 150 trials.

    Time frame: Online task performance assessed online before lab-visits (approximately 10 days)

  4. Metabolic state x stimulation-induced changes in the number of rewards collected under threat (VR task)

    The number of rewards collected during a VR foraging task will be compared between two different metabolic states (fasted vs. postprandial) and stimulation conditions (tVNS vs. sham).

    Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)

Secondary outcomes

  1. BOLD response during the effort-trade-off task (feedback-phase)

    The outcome describes task-evoked neural activation (BOLD response) during the feedback phase of the effort trade-off task. Neural activation is measured as a task-evoked BOLD response during feedback presentation.

    Time frame: Collected during fMRI session (single session throughout study completion ~35min per participant)

  2. Choices in the effort trade-off task

    Choices in the effort trade-off task will be assessed as a binary outcome of accept vs. reject.

    Time frame: During a single fMRI session throughout study completion (approximately 3 weeks)

  3. Association between BOLD response during the effort-trade-off task (offer-phase) and effort discounting

    The primary outcome is the association (regression coefficient) quantifying the relationship between effort discounting and neural activation (BOLD response) during the offer-phase of an effort trade-off task. Neural activation is measured as a task-evoked BOLD response during offer presentation. Effort discounting is estimated from behavioral choices in the effort trade-off task using computational modeling.

    Time frame: During a single fMRI session throughout study completion (approximately 3 weeks)

  4. Association between BOLD response during the effort-trade-off task (feedback phase) and effort-discounting

    The primary outcome is the association (regression coefficient) quantifying the relationship between effort-discounting and neural activation (BOLD response) during the feedback phase of an effort trade-off task. Neural activation is measured as task-evoked BOLD response during feedback presentation.Effort-discounting is estimated from behavioral choices in the effort trade-off task using computational modeling.

    Time frame: During a single fMRI session throughout study completion (approximately 3 weeks)

  5. Effort-discounting

    The outcome describes effort-discounting derived from the effort trade-off task. Effort-discounting is estimated from behavioral choices in the effort trade-off task using computational modeling.

    Time frame: During a single fMRI session throughout study completion (approximately 3 weeks)

  6. Association between BOLD responses during effort trade-offs and number of rewards during VR

    The primary outcome is the association (regression coefficient) quantifying the relationship between individual differences in foraging during VR and task-evoked neural connectivity. Task-evoked BOLD responses during the effort trade-off task is measured using functional magnetic resonance imaging (fMRI). Foraging in the VR task is the number of rewards collected.

    Time frame: Neural data: During a single fMRI session throughout study completion (approximately 3 weeks); Behavioral data: During sham stimulation session throughout study completion (approximately 3 weeks)

  7. Association between neural connectivity and number of rewards during VR

    The primary outcome is the association (regression coefficient) quantifying the relationship between individual differences in effort-discounting and task-evoked neural connectivity. Task-evoked neural connectivity during the effort trade-off task is measured using functional magnetic resonance imaging (fMRI). Neural connectivity is quantified as region-of-interest-level functional connectivity. The number of rewards is measured in the VR foraging task.

    Time frame: Neural data: During a single fMRI session throughout study completion (approximately 3 weeks); Behavioral data: During sham stimulation sessions throughout study completion (approximately 3 weeks)

  8. Stimulation-induced changes in time spent foraging under threat (VR foraging task)

    The primary outcome is the comparison of time spent foraging (seconds) during the VR foraging task between stimulation conditions (tVNS vs. sham).

    Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)

  9. Stimulation-induced changes in escape latency under threat (VR foraging task)

    The primary outcome is the comparison of escape latency (seconds) during the VR foraging task between stimulation conditions (tVNS vs. sham).

    Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)

  10. Stimulation-induced changes in threat-evoked heart rate increase (VR foraging task)

    The primary outcome is the comparison of heart rate increases following threat during the VR foraging task between active vs. sham tVNS. Autonomic responses to threat are operationalized as the change in heart rate from a pre-threat baseline period (safety period preceding the trial) to the first minute following threat onset.

    Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)

  11. Stimulation-induced changes in heart rate recovery following threat (VR foraging task)

    The primary outcome is the comparison of heart rate recovery following threat response during the VR foraging task between stimulation conditions (tVNS vs. sham).

    Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)

  12. Stimulation-induced changes in habituation of heart rate responses following threat (VR foraging task)

    The primary outcome is the comparison of habituation of heart rate response following threat over trials during the VR foraging task between active vs. sham tVNS.

    Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)

  13. Stimulation-induced changes in subjective metabolic state (VR foraging task)

    The primary outcome is the comparison of the change in subjective metabolic state after receiving a caloric load between stimulation conditions (tVNS vs. sham). Subjective metabolic state assessed during a VR foraging task using 0-100 Visual Analog Scales (VAS) of hunger and satiety. A metabolic state score is calculated as the difference between hunger and satiety ratings, scaled from -1 to 1 ((hunger-satiety)/100). The difference will then be compared between stimulation conditions.

    Time frame: During each stimulation session (tVNS vs. sham) throughout study completion (approximately 3 weeks)

  14. Stimulation-induced changes in affect (PANAS)

    The primary outcome is the comparison of affect between stimulation conditions (tVNS vs. sham). Affective state is assessed using the Positive and Negative Affect Schedule (PANAS), administered as Visual Analog Scales (0-100). A composite affect score (positive - negative affect) is calculated from positive and negative affect ratings.

    Time frame: During each stimulation session (tVNS vs. sham) throughout study completion (approximately 3 weeks)

  15. Metabolic state x stimulation-induced changes in affect (PANAS)

    The primary outcome is the comparison of affect between metabolic state (fasted vs. postprandial) and stimulation condition (tVNS vs. sham). The primary analysis examines the interaction between metabolic state and stimulation condition. Affective state is assessed using the Positive and Negative Affect Schedule (PANAS), administered as Visual Analog Scales (0-100). A composite affect score (positive - negative affect) is calculated from positive and negative affect ratings.

    Time frame: During each stimulation session (tVNS vs. sham) throughout study completion (approximately 3 weeks)

  16. Metabolic state x stimulation-induced changes in time spent foraging under threat (VR task)

    The primary outcome is the comparison of time spent foraging (seconds) during a VR foraging task between metabolic state (fasted vs. postprandial) and stimulation condition (tVNS vs. sham). The primary analysis examines the interaction between metabolic state and stimulation condition.

    Time frame: During each stimulation session (active and sham) throughout study completion (approximately 3 weeks)

  17. Metabolic state x stimulation-induced changes in escape latency under threat (VR task)

    The primary outcome is the comparison of escape latency (seconds) during a VR foraging task between metabolic state (fasted vs. postprandial) and stimulation condition (tVNS vs. sham). The primary analysis examines the interaction between metabolic state and stimulation condition.

    Time frame: During each stimulation session (tVNS and sham) throughout study completion (approximately 3 weeks)

  18. Response times in the online task

    The outcome describes response times collected during the online task. Response times (milliseconds) are collected in trials of the online reward learning task (10 runs with 150 each).

    Time frame: Assessed online before lab-visits (approximately 10 days)

  19. Choice accuracy in the online task

    Choice accuracy (binary correct vs. incorrect) is derived from trials of the online reward learning task (10 runs with 150 each).

    Time frame: Assessed online before lab-visits (approximately 10 days)

  20. Metacognitive calibration (performance-rating coupling)

    The outcome describes metacognitive calibration in a reward learning task. Self-reported ratings are collected at the end of each run (10 runs) on a Visual Analog Scale (0-100 Visual Analog Scale) assessing subjective performance. Higher values represent better subjective performance. A metacognitive calibration score will be calculated as the difference between self-reported performance and objective task performance.

    Time frame: Assessed online before lab-visits (approximately 10 days)

  21. Ecological Momentary Assessments (EMA) for mood

    The outcome describes a mood state score calculated from data collected during the online reward learning task. EMA questions (0-100 Visual Analog Scale) assessing mood state (happy and sad) will be asked before every run of the online task (10 runs). Mood state will be calculated as happy - sad.

    Time frame: Assessed online before lab-visits (approximately 10 days)

  22. Ecological Momentary Assessments (EMA) for stress

    The outcome describes the stress rating of participants collected during the online reward learning task. EMA question (0-100 Visual Analog Scale) assessing subjective stress will be asked before every run of the online task (10 runs).

    Time frame: Assessed online before lab-visits (approximately 10 days); EMA data: Collected before every online session (x 10)

  23. Association between Ecological Momentary Assessments (EMA) and response times in the online task

    The primary outcome is the association (regression coefficient) quantifying the relationship between mood state and response times. Response times (seconds) are derived from trials of the online reward learning task (10 runs with 150 trials each). EMA questions (0-100 Visual Analog Scale) assessing mood (happy - sad) are asked before every run of the online task (10 runs).

    Time frame: Assessed online before lab-visits (approximately 10 days)

  24. Association between BOLD response during the effort-trade-off task and tVNS-induced changes in the number of rewards collected

    The primary outcome is the association (regression coefficient) quantifying the relationship between neural activity and behavioral tVNS response. tVNS response is defined as the within-subject change in the number of rewards collected during VR foraging under active vs sham tVNS. Neural activation is measured as task-evoked BOLD response.

    Time frame: Neural markers: Collected during fMRI session (single session, ~30 min per participant); Behavioral data: Collected during VR sessions with two visits per participant (throughout study completion, approx. 3 weeks)

  25. Association between neural connectivity and tVNS-induced changes in number of rewards collected

    The primary outcome is the association (regression coefficient) quantifying the relationship between neural connectivity and behavioral tVNS response. Behavioral response is defined as the within-subject change in the number of rewards collected during VR foraging under tVNS vs sham. Neural connectivity markers derived from fMRI-testing will be used to assess how neural connectivity explains interindividual variability in behavioral tVNS response.

    Time frame: Neural markers: Collected during fMRI session (single session, ~30 min per participant); Behavioral data: Collected during VR sessions with two visits per participant (throughout study completion, approx. 3 weeks)

  26. Associations between baseline cortisol and neural activation

    The primary outcome is the association (regression coefficient) quantifying the relationship between cortisol and BOLD response during the effort-trade-off task. Morning serum cortisol will be collected after an overnight fast at the laboratory visit immediately before the MRI session and quantified in nmol/L (expected range approx. 140-690nmol/L). Neural activation is measured as task-evoked BOLD response.

    Time frame: Blood draw: Collected before the MRI session; Neural activation: During a single MRI session throughout study completion (approx. 3 weeks)

  27. Association between baseline cortisol and tVNS-induced changes in the number of rewards collected

    The primary outcome is the association (regression coefficient) quantifying the relationship between cortisol and behavioral tVNS response. Morning serum cortisol will be collected after an overnight fast at the laboratory visit immediately before the MRI session and quantified in nmol/L (expected range approx. 140-690nmol/L). Behavioral response is defined as the within-subject change in number of rewards collected during VR foraging under active vs sham tVNS.

    Time frame: Blood draw: Collected before the MRI session, Behavioral data: Collected during VR sessions with two visits per participant (throughout study completion, approx. 3 weeks)

  28. Association between insulin resistance and BOLD response during the effort-trade-off task

    The primary outcome is the association (regression coefficient) quantifying the relationship between the value of insulin resistance and neural activation (BOLD responses) during an effort-trade-off-task. Neural activation is measured as task-evoked BOLD response. Insulin resistance is assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting plasma insulin and glucose concentrations obtained from morning blood samples.

    Time frame: Blood samples and neural activation assessed during a single MRI session throughout study completion (approximately 3 weeks)

  29. Association between insulin resistance and tVNS-induced changes in number of rewards collected

    The primary outcome is the association (regression coefficient) quantifying the relationship between insulin resistance and behavioral stimulation response during a VR foraging task. Behavioral response to tVNS is measured as the change in the number of rewards collected under threat during a VR foraging task. Insulin resistance is assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting plasma insulin and glucose concentrations obtained from morning blood samples.

    Time frame: Behavioral outcomes and biomarker measures assessed throughout study completion (approximately 3 weeks)

  30. BMI (Body-Mass-Index)

    Body mass index will be included as a covariate in analyses involving metabolic, neural, and behavioral outcomes.

    Time frame: Collected throughout study completion (approximately 3 weeks)

  31. Association between Ecological Momentary Assessments (EMA) and reward learning in the online task

    The primary outcome is the association (regression coefficient) quantifying the relationship between mood state and reward learning. Reward learning is measured in the online reward learning task (10 runs with 150 trials each). EMA questions (0-100 Visual Analog Scale) assessing mood (happy - sad) are asked before every run of the online task (10 runs).

    Time frame: Assessed online before lab-visits (approximately 10 days)

Other outcomes

  1. SHAPS (Snaith-Hamilton Pleasure Scale)

    Self-report questionnaire assessing anhedonia severity. Used for grouping participants and associated with behavioral and neural outcomes. Total scores range from 14 to 56 with higher scores reflecting higher anhedonia.

    Time frame: Assessed online before lab-visits (approximately 10 days)

  2. TEPS (Temporal Experience of Pleasure Scale)

    Questionnaire measuring anticipatory and consummatory pleasure. This outcome will be associated with behavioral and neural outcomes. Total scores range from 18 to 108 with subscales scoring between 10-60 (anticipatory) and 8-48 (consummatory). Higher scores indicate greater hedonic capacity (lower anhedonia) while lower scores represent higher anhedonia symptoms.

    Time frame: Assessed online before lab-visits (approximately 10 days)

  3. DARS (Dimensional Anhedonia Rating Scale)

    Questionnaire assessing multiple facets of anhedonia. This outcome will be associated with behavioral and neural outcomes. Total scores range from 0 to 68, with subscales scoring between 0-16 (hobbies, food, and social) and 0-20 (sensory). Higher scores indicate greater hedonic capacity (lower anhedonia) while lower scores represent higher anhedonia symptoms.

    Time frame: Assessed online before lab-visits (approximately 10 days)

  4. STAI (State-Trait Anxiety Inventory)

    Self-report questionnaire assessing trait anxiety. This outcome will be associated with behavioral and neural outcomes. Total scores range from 20 to 80 with higher scores indicating higher anxiety.

    Time frame: Assessed online before lab-visits (approximately 10 days)

  5. BDI-II (Beck Depression Inventory-II)

    Questionnaire assessing depressive symptoms. Used as an additional symptom dimension. Total scores range from 0 to 63, with higher scores indicating greater depressive symptom severity.

    Time frame: Assessed online before lab-visits (approximately 10 days)

  6. Metacognition

    Five questions (0-100 Visual Analog Scale) evaluating self-rated performance, self-rated performance compared to the days before, self-rated performance compared to others. Higher scores indicate better self-rated performance.

    Time frame: Assessed online before lab-visits (approximately 10 days)

  7. EMA (Ecological Momentary Assessment)

    Ecological Momentary Assessments (EMA) using 0-100 Visual Analog Scale, administered repeatedly across online-task and lab sessions to capture current internal states (distraction, satisfaction, physical state, mental well-being, caloric intake, thirst, motivation).

    Time frame: Assessed online before lab-visits (approximately 10 days) and during each lab-session throughout study completion (approximately 3 weeks)

  8. Waist-to-hip Ratio

    Waist-to-hip ratio will be included as a covariate in analyses involving metabolic, neural, and behavioral outcomes.

    Time frame: Collected throughout study completion (approximately 3 weeks)

  9. Cortisol

    Morning serum cortisol will be collected after an overnight fast at the laboratory visit immediately before the MRI session and quantified in nmol/L (expected range approx. 140-690nmol/L). Cortisol will be included as a covariate in analyses involving metabolic, neural, and behavioral outcomes.

    Time frame: Collected throughout study completion (approximately 3 weeks)

  10. Insulin Resistance

    Insulin resistance is assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting plasma insulin and glucose concentrations obtained from morning blood samples. A higher score indicates less insulin sensitivity. HOMA-IR will be included as a covariate in analyses involving metabolic, neural, and behavioral outcomes.

    Time frame: Collected throughout study completion (approximately 3 weeks)

  11. STICSA (State-Trait Inventory for Cognitive and Somatic Anxiety)

    Questionnaire measuring state and trait anxiety. Used for grouping participants and associated with behavioral and neural outcomes. Total scores range from 21 to 84, with subscales scoring between 11-44 (somatic anxiety) and 10-40 (cognitive anxiety). Higher scores indicate higher anxiety.

    Time frame: Assessed online before lab-visits (approximately 10 days)

07

Study locations

1 of 1 sites recruiting
  • University Hospital Bonn, Bonn, Germany
    Bonn, 53127, Germany
    Recruiting
08

References and documents

Publications

  • Neuser MP, Teckentrup V, Kuhnel A, Hallschmid M, Walter M, Kroemer NB. Vagus nerve stimulation boosts the drive to work for rewards. Nat Commun. 2020 Jul 16;11(1):3555. doi: 10.1038/s41467-020-17344-9. PubMed 32678082 ↗

Individual participant data

Plan to share: Yes — After the publication of the key results of the study, anonymized data will be made publicly available (e.g., at osf.org)

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data will become available after an embargo period of 12 months after completion of the study.

Access criteria: Until the data is publicly available, researchers may contact the lead PI to gain access.

Data sharing details ↗ · neuromadlab.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 21 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Mar 17, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07476469
Lead sponsor
Dr. Nils B. Kroemer
Collaborators
University of Bonn, Else Kröner Fresenius Foundation
Responsible party
Dr. Nils B. Kroemer (Prof. Dr. rer. nat., University of Bonn) — Sponsor-investigator
First posted
Mar 17, 2026
Start date
Mar 23, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 23, 2026

Study contacts

Dr. Anne Kühnel
Contact
akuehnel@uni-bonn.de
+49 228 28711519

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion